Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Nov 10, 2022 (4 years ago)

Phenoxybenzamine Hydrochloride Capsules

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Impurities/Degradation Specifications

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Phenoxybenzamine Hydrochloride Capsules, USP 10mg, 100-count bottles, RX only Dist. by: Par Pharmaceutical Chestnut Ridge, NY 10977 U.S.A. Mfg. by: Par Forumulations Private Limited,9/215, Pudupakkam, Kelambakkam - 603 103. NDC 49884-038-01

Affected NDC 49884-0038-01

Compare with the code on your package — it is the most precise check available.

Drug: Phenoxybenzamine

Recalling firm
Par Formulations Private Limited
NDC code
49884-038-01
Origin
N/A, India
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0061-2023 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Phenoxybenzamine recalls

See all
Class II · Moderate risk

Phenoxybenzamine HCl active pharmaceutical ingredient packaged in…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-840-2015

Other impurity / degradation recalls from 2022

All impurity / degradation recalls
Class II · Moderate risk

Glycopyrrolate Tablets

Failed impurities/degradation specifications: Out of specification for unknown impurities.

Completed Impurity / degradation Avkare LLC NDC 50268-363-15 D-0091-2023